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INTRODUCTION 
 
Human parturition has been termed „labour‟ in recognition of the hard work 
that the parturient as well as the uterine myometrium have to perform in order to 
deliver the fetus. Labour refers to the onset of effective uterine contractions 
leading to progressive effacement and dilatation of the cervix resulting in the 
expulsion of the fetus, placenta and the membranes. 
WHO defines normal labour as “spontaneous in onset, low risk at the start 
of the labour and remaining so throughout labour and delivery”. The infant is born 
spontaneously in the vertex position between 37 and 42 completed weeks of 
pregnancy. After birth, mother and infant are in good condition” 
According to Turnbull (1976) - “The spontaneous onset of labour is a 
robust and effective mechanism…. And should be given to operate on its own. 
We should only induce labour when we are sure that we can do better”. 
The ideal method of induction of labour would mimic exactly the onset of 
spontaneous labour. Not surprisingly no method of induction currently available 
does this. 
Induction is indicated when the benefits to either the mother or the fetus 
outweigh those of continuing the pregnancy. 
The American college of Obstetricians and Gynecologists (1999a) does not 
support elective induction, except for logistical reasons such as risk of rapid 
2 
 
labour, the women lives a long distance from the hospital or for psychosocial 
indications. 
Induction of labour has two important components, cervical ripening and 
stimulation of uterine contractions to achieve dilatation of cervix and delivery of 
the fetus It is well recognized that the success of induction of labour, which 
ultimately aims at achieving vaginal delivery depends to a great extent on the 
favorability of the cervix or its readiness to go into labour. Agents used for 
cervical ripening may lead in the establishment of contractions to women with 
unfavorable cervix. 
Pharmacological methods like Prostaglandins (PGE1 + PGE2) relaxin and 
mechanical methods like membrane stripping, trans cervical catheter, Hygroscopic 
cervical dilators etc are available for preinduction cervical ripening. 
Mifepristone is a 19 nor – Steroid with a greater affinity for the 
progesterone receptor and thus blocks the action of progesterone at a cellular level. 
As a fall in the level of progesterone considered one of the important events in the 
onset of spontaneous labour, it therefore seems likely that this drug may be useful 
on induction. 
A number of studies have looked at the efficacy of mifepristone on cervical 
ripening. There is a reduction in the induction delivery interval when induction is 
performed after mifepristone and a trend to a reduction in the rate of ceasarean 
section (Wing et al 2000). 
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AIMS AND OBJECTIVES 
 
 
1. To study the effectiveness and safety of mifepristone as a cervical 
priming agent for induction of labour. 
2. To compare the effect of mifepristone in study group with a control 
group of same size. 
3. To study improvement in bishop score. 
4. Necessity for augmentation of labour. 
5. To study induction delivery interval. 
6. Maternal and fetal outcome. 
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REVIEW OF LITERATURE 
 
Induction of labour: 
 Induction of labor is common in obstetric practice. According to the most 
current studies, the rate of induction varies from 9.5 to 33.7 percent of all 
pregnancies annually. In the absence of a ripe or favorable cervix, a successful 
vaginal birth is less likely. 
The amount of uterine pressure to dilate a ripe cervix is thought to be 
approximately 1600 mm Hg, while the pressure to dilate an unripe cervix is 
estimated to be greater than 5 times that, or 10,000 mm Hg. Therefore, cervical 
ripening or preparedness for induction should be assessed before a regimen is 
selected 
DEFINITION: 
INDUCTION:  
 Induction implies stimulation of contractions before the spontaneous onset 
of labour, with or without ruptured membranes. 
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AUGMENTATION:  
 Refers to the enhancement of spontaneous contractions that are considered 
inadequate because of failed cervical dilatation and fetal descent. 
HISTORY:- 
 The human race for centuries found reasons to interfere with pregnancy by 
trying to hasten its conclusion. Often this consisted of attempts to procure the 
abortion of unwanted pregnancies, but other more positive motives arose from the 
desire to relieve the mother of a life threatening pregnancy or to achieve 
mechanically more favorable vaginal delivery of a smaller premature baby through 
a constricted birth canal. Through time, as a better perception of fetal and maternal 
risks developed alongside more efficient methods of labour induction, the 
indications shifted more commonly to serve the interest of the fetus perceived to 
be in jeopardy. 
 The first reliable technique to be used widely in obstetric practice was 
amniotomy-artificial rupture of membranes. Although this procedure had probably 
been employed much earlier it first entered the medical literature in 1756. When 
Thomas Denman (1733-1815) of middle sex hospital of London wrote extrolling 
its virtues. As a result it became known within Europe as the „English method‟. 
 Another mechanical method was devised in 1861 by Robert Barnes (1817-
1907) of London, Using a hydrostatic bag placed through the cervix and filled 
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with water with a view to labour induction. A similar approach was later taken by 
Camille champetier de Ribes (1848-1935) in Paris and by James Vorhees (1869-
1929) in Newyork. 
 More than a century later modern obstetricians would follow the same 
principle using a foley catheter, but by now understanding that the modus operandi 
was the local release of prostaglandins. 
 Hind water rupture with Drew Smythe Catheter was introduced in 1931, but 
what gains in safety in terms of forewater preservation with reduced risk of 
Amniotic fluid infection and cord prolapse. It loses in efficiency when compared 
with forewater rupture. 
 Sir Henry Dale (1815-1968) made the first observation that posterior 
pituitary caused uterine contractions. Pitocin was first extracted from the posterior 
pituitary gland in 1906, and Blair– Bell described its application in the pregnant 
uterus in 1909. 
 In 1910, it was used for augmentation in cases of uterine inertia, but 
maternal deaths from shock were reported after intramuscular injection of pitocin. 
Its use for induction was first reported by Theobald in 1952. 
 Oxytocin is the first polypeptide hormone synthesised by Du. Vigneaud and 
Coworkers, 1953. „Physiological drip‟ (or) dilute intravenous infusion was 
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introduced by Geoffrey Theobald pharmacologically sound approach of oxytocin 
titration was introduced by Alec Turnbull and Anne –Anderson (1960). 
 Prostaglandin was first isolated from seminal fluid of monkeys, Sheep and 
Goat, by ulf von Euler at the Koralinska institute in stockholm in 1935. Elias corey 
Synthesized dinoprostone in 1970 at the Harvard University Bergstrom, 
Samuelson and vane jointly received the 1982 Nobel Prize for their discovery of 
prostaglandins. 
RU -486 (or) mifepristone:- 
 The Compound was discovered by Researchers at Roussel uclaf of France 
in 1980 while they were studying glucocorticoid receptor antagonists. Etenne – 
Emile Baulieu recognized its anti progestrone activities and saw its potential for 
the induction of medical abortion the drug was first licensed in France in 1988, for 
use in Combination with a Prostaglandian, under the name of mifegyne. 
Indications for Induction of Labour 
 The indications for induction of labour are, where the benefits of delivering 
the fetus at a specified point of time, outweighs the benefits of allowing the 
pregnancy to continue. There are two main types of induction, namely Indicated 
Induction and Elective induction.  
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a. Indications for Induction of Labour: 
1. For high risk pregnancies where there is risk to both the mother and the fetus. 
a. Preclampsia and eclampsia Hypertension  
b. Renal disease complicating pregnancy. 
c. Premature rupture of membranes and chorioamnionitis. 
2. Where there is increased likely risk to mother, if termination is not advocated 
1. Intrauterine death 
2. Abruptio placenta 
3. Where the fetus is at risk 
1. Post term pregnancies 
2. Chronic placental insufficiency 
3. Rh isoimmunisation 
4. Maternal diabetes complicating pregnancy 
5. Previous unexplained still births 
6. Intrauterine growth restriction 
7. Anamalous baby. 
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b. Elective induction 
Logistic factors such as distance from the hospital or a history of rapid labor 
and delivery may be reasonable indications. But elective induction (without 
medical or obstetric indications) is generally not recommended. 
c. Contra indications 
1. When vaginal delivery is contraindicated- 
a) Major degrees of cephalo pelvic disproportion 
b) Previous VVF repair 
c) Pelvic tumour 
d) Carcinoma cervix 
e) Active gential herpes infection. 
 
2. Malpresentations. 
3. Placental abnormalities like Vasa praevia and Type III and IV placenta praevia. 
4. Appreciable macrosomia 
5. Severe hydrocephalus 
6. Non reassuring fetal heart rate 
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Outcome of Induction 
Factors influencing the outcome of induction 
The process of prelabour cervical softening and dilatation is a part of a continuum, 
which culminates in spontaneous labour. 
 The success of any method of induction depends largely on (1) Parity and 
(2) The state of cervix at the beginning of induction. In most centers, the modified 
Bishop score (1964) is used to assess the favorability of the cervix both prior to 
and following induction.The partogram aids in assessing the progress of labour. 
 Some definitions, useful for assessing the success or failure of induction are 
enlisted below. 
Successful Induction: 
 Successful induction is defined as (“Vaginal delivery of an infant in good 
condition with minimum maternal discomfort and side effects, within a specified 
framework of time”). 
Failed Induction: 
 Defined by Duff et al (1984), (as the failure to enter the active phase of 
labour, after twelve hours of regular uterine contractions). Failed Induction, is 
diagnosed when, a patient who was induced, does not deliver vaginally, in the 
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absence of fetal distress, with acute events like abruption or cord prolapse and 
failure of progress due to cephalopelvic disproportion or malposition and or if the 
patient has not entered the active phase of labour despite adequate management for 
twelve hours (Arulkumaran et al 1985). 
RISKS OF INDUCTION OF LABOUR:- 
Increase in ceasaren Section rate: 
 The risk of ceasarean section increased nearly threefold in primigravid 
women (11.8% Vs 27.9%) and doubled in multigravid women (3.4% Vs 8.5%) 
who were induced compared to those labouring spontaneously (RCOG 200 lb). 
Uterine Hyper Contractility:- 
 Uterine hypertonus is defined as a single uterine contraction that lasted 2 or 
more minutes. 
 Tachysystole is defined as at least 12 contractions in 20 minutes. 
Hyperstimulation is defined as either hypertonus (or) tachysystole associated with 
abnormal FHR pattern. 
 Misoprostol was associated with significantly increased risk of tachysystole 
or hyper stimulation when compared with PGE 2 gel (WING and Coworkers 
1995a, 1995b). 
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 Induced labour is associated with on increased risk of postpartum 
hemorrhage. 
 Prolonged induction is associated with a small increase in the risk of 
infectious morbidity with an estimated 10% incidence noted after 40hrs of 
induction (Bahn et al 1998). 
Oxytocin induction has been reported to increase the risk of neonatal 
Hyperbilirubinemia. 
Iatrogenic prematurity occurs inadvertently and a review of the gestational 
age prior to induction is essential. 
The reasons for the rising rates of induction of labour can be complex and 
multifactorial (Rayburn and Zhang 2002). 
Some of them are: 
 Improved ability of physicians to determine gestational age accurately 
with early dating scans, thus avoiding the possibility of iatrogenic 
prematurity. 
 Widespread availability of cervical ripening agents 
 Improved knowledge of methods and indications for induction 
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 More relaxed attitudes towards marginal/elective indications, both of 
the physician and the patient 
 Litigation constraints. 
Counseling the couple prior to induction: 
 It is essential to have good communication with the woman and her family 
prior to induction; wherever possible this should be supported by evidence-based 
and preferably, written information. While counseling, the following need to be 
discussed (RCOG 2008): 
 The indications for induction; more specifically, the risk associated with 
continuing the pregnancy 
 The time and procedure of induction 
 Arrangements for support during labour 
 Pain relief measures since induced labour may be more painful. 
 The need for close monitoring of the fetal heart rate (including electronic 
fetal monitoring in labour) 
 Alternative options available to the mother if she refused induction 
 The risks associated with induction of labour, specifically with the 
inducing agent used. 
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The chances of failure of induction and the options available in case of 
failure  
Criteria of an ideal inducing agent: 
An ideal inducing agent is one which: 
 Achieves onset of labour within the shortest possible time. 
 Does not result in greater pain and hence does not require greater 
analgesics as compared to spontaneous labour 
 Has a very low incidence of failure to induce labour 
 Does not increase the rate of cesarean or operative vaginal deliveries as 
compared to spontaneous labour. 
 Does not increase perinatal morbidity compared to spontaneous labour. 
We are yet to find an ideal inducing agent. Hence, the decision for induction 
should be well thought out and communicated to the woman concerned. 
PRE INDUCTION CERVICAL RIPENING:- 
 The condition of the cervix is important to the Success of labour Induction, 
Cervical scoring was first described by Bishop in 1964. Various modifications of 
Bishops original score have been suggested and the most widely used is 
CALDER‟S MODIFIED BISHOP‟S SCIRE (1974). 
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Score 0 1 2 3 
Dilatation (cm) < 1 1-2 2-4 >4 
Effacement (cm) >4 2-4 1-2 >1 
Station (cm) -3 -2 -1,0 +1,+2 
Consistency Firm Average Soft  
Position Posterior Mid-   
  Anterior   
 
 
 
A score of 9 conveys a high likelihood for a successful induction. For 
research purposes a Bishop score of 4 (or) less identifies as unfavorable cervix and 
may be an indication for cervical Ripening. 
Cervical ripening is the process by which the cervix becomes soft, 
compliant & partially dilated. It is a fundamental process that must occur, if 
parturition is to progress smoothly. 
Cervical ripening is due to a combination of Biochemical. Endocrine, 
mechanical and possibly inflammatory events. It is believed that the increasing 
myometrial contractility, in the form of Braxton Hicks contractions seen with 
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advancing gestation plays a vital role in the effacement of cervix, prior to the 
actual commencement of labour. 
  
 
 
  
 Structurally, the cervix is mainly composed of collagen, as opposed to the 
myometrium, which predominantly consists of Smooth muscle. There are four 
types of collagen in the human body – I, II, III, IV. 
The cervix is predominantly composed of types I (66 percent) and III (33 
percent). The firmness of the cervix in the non-pregnant state is mainly due to the 
properties of these collagen fibrils. These bundles in turn are embedded in ground 
substance consisting of proteoglycans. 
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The proteoglycans are made of a central core of proteins which are linked 
to glycosaminoglycans, which are repeating disaccharide units composed of a 
hexosamine (glucosamine (or) galactosamine) and an uronic acid (glucuronic acid 
or iduronic acid) residue. 
In the cervix, the main glycosaminoglycans are dermatan sulphate and 
chondroitin sulphate, both of which are highly negatively charged and 
hydrophobic. Hence, they repel water and are responsible for the firmness of the 
cervix. Moreover, by interacting with the central protein core as well as among 
them, glycosaminoglycans facilitate the optimum orientation of the collagen 
fibrils, enhancing, the mechanical strength of the cervix. 
Towards term, the glycosaminoglycan Concentration alters and the 
dermatan and chondroitin sulphate are replaced by hyaluronic acid, which has 
different physio chemical properties. 
Hyaluronic acid is hydrophilic and imbibes water Accumulation of water 
within the substance of the cervix destabilises the collagen fibrils, contributing to 
cervical ripening. 
The water content of the human cervix increases from 80 percent in the 
non- pregnant state, to 86 percent in late pregnancy (Liggins 1978; Uldbjerg et al 
1983a). The accumulation of water in between the collagen fibrils has a scattering 
or dispersing effect, resulting in reduced mechanical strength. 
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Collagenase & leukocyte elastase levels are found to increase with 
advancing gestation and are associated with progressive decline in the 
concentration of cervical collagen. (Uldbjerg et al 1983 b). 
The mature collagen, which has many crosslinks that are responsible for its 
tensile strength, is replaced by an immature collagen which has a few cross links. 
Ganstrom et al (1991) have shown that the insufficient remodelling of 
collagen during pregnancy is an independent factor that results in labour. 
METHODS OF CERVICAL RIPENING:- 
There has often been an attempt to make a distinction between women who 
are undergoing cervical ripening and women who are being formally induced. This 
tendency is artificial, as in all the intention is to artificially stimulate the onset of 
labour. 
Women undergoing cervical ripening are simply those in whom there is an 
unfavourable cervix and where the indication allows the greater time expected for 
induction to establish active labour. 
As the first stage of labour is a seamless progression from the latent into 
active phase, so induction is a progression from cervical ripening through to the 
onset of contractions. 
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Agents used for cervical ripening may lead to the establishment of 
contractions in women with an unfavourable cervix. Many agents can be used in 
both women with high and low cervical scores, albeit with a different expectation 
of the time likely before delivery will be achieved. 
Non-Pharmacological methods:- 
Sexual intercourse, herbal remedies, castor oil, enemas, acupuncture, baths. 
No Study has shown any proven benefit of these therapies for induction of labour. 
Sweeping of membranes:- 
 It is an old method of inducing labour described by Hamilton in 1810. 
 Mc Colgin and Collegues (1990) reported that two thirds of women who 
underwent stripping entered spontaneous labour within 72 hours. 
The procedure of membrane sweeping causes an increase in the levels of 
Prostoglandin F2 alpha (Mc colgin et al 1993). 
Bouvelian and colleagues (1999) – Sweeping the membranes as a routine at 
term reduced the chances of pregnancy progressing beyond 41 weeks and reduce 
the need for induction of Labour from 36 to 21%. 
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Mechanical methods:- 
Intrauterine Extraamniotic Foley Catheter with bulbi inflation to 30ml
 -  Rapid improvement in Bishop Scores And shorter labours (Sherman 
and Colleagues 1996).  
Bujold and coworkers (2004) reported a lower incidence of success when 
induction by Foley catheter was compared with that by oxytocin – 56 versus 78 
percent. 
Extra – amniotic saline infusion (EASI):- 
Abromovici and coworkers (1999) reported that 85 percent of those 
induced by catheter infusion delivered within 24hrs compared with 55 percent of 
those given misoprostol. 
Mullin and associates (2002) reported that mean induction to delivery 
interval was shorter in the catheter plus oxytocin group. 
Hygroscopic cervical dilators:- 
Guinn and co-workers (2000) reported a longer induction to delivery 
interval with cervical dilators plus oxytocin compared with that of EASI Plus 
oxytocin. 
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The use of hygroscopic dilators appear to be safe, although anaphylaxis has 
followed laminaria insertion (Cole and Neek 2000) 
The attraction of dilators is their low cost and ease of placement and 
removal. 
As mechanical methods are believed to facilitate ripening by causing local 
release of Prostaglandin their use has been superseded by administration of local 
prostaglandin in most units. 
Pharmacological methods:- 
Prostaglandins:- 
Prostaglandins probably induce cervical ripening by producing 
vasodilatation of the cervical blood vessels and increased extravasation of the 
neutrophil (Rajabi et al 1988). 
The extravasated neutrophils then degranulate and release large quantities 
of collagenases and proteases which degrade cervical collagen and soften the 
structure of the cervix (Rajabl et al 1988). 
Prostaglandins act synergistically with interleukin 8 (IL -8) to stimulate the 
fibroblasts to produce hyaluronic acid (Ogavia et al 1998) which in turn alters the 
composition and structure of the cervix. 
22 
 
This effect on the cervix along with uterotonic effects of prostaglandins and 
other uterotonics on the uterus enables the cervix to efface and dilate during 
labour to allow parturition. 
Prostaglandin E2:- 
Compared to the placebo, the induction of labour with a vaginal 
prostaglandin gel has been consistently shown in several trials to be associated 
with and increased Bishop score and a reduced incidence of ceasarean section 
(Brennand and Green 1998). 
The United Kingdom‟s national institute for clinical Excellence (NICE) 
Guidelines on the induction of labour recommends that prostaglandin E2 should 
be used in preference to oxytocin for the induction of labour in women with intact 
membrane regardless of their parity or the ripeness of the cervix. 
In women with term prelabour rupture of membranes Prostaglandin 
(dinoprostone PGE2) and oxytocin are equally effective for the induction of 
labour, regardless of their parity (or) the state of the cervix (Tan and Hannah 
2000). 
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Prostaglandin E1:- 
1. Misoprostol use may decrease the need for oxytocin achieve higher rates of 
vaginal delivery within 24hrs of induction and reduce induction – delivery 
intervals. (Sanchex – Ramos and colleagues, 1997). 
2. The committee on obstetrics and gynecologists (1999 b) recommended the 
use of a 25ug intravaginal dose. 
3. Data from the United Kingdom Cochrane centre support these 
recommendations. But the investigators cautioned that increased uterine 
hyperstimulation with adverse fetal heart rate changes was of concern 
(Hotmeyr and associates, 1999). 
4. In December 2000, the American college of obstetricians and 
Gynecologists reaffirmed its recommendation for use of the drug because 
of proven safety and efficacy. 
5. A 25 microgram dose was found comparable to dinoprostone gel (Van 
Gemund and associates, 2004). 
OXYTOCIN:- 
In modern obstetric practice oxytocin is more commonly used in 
combination with amniotomy making it unsuitable for use in women who have 
cervical scores below 6. 
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When compared to induction with prostaglandins evidence suggests that 
oxytocin induction is associated with a lower chance of delivery within 24hours. 
In women with an unfavourable cervix, induction with oxytocin was 
associated with higher rates of ceasarean section. 
Lower dose regimens are recommended with starting doses of 1-2 milli 
units / min, increased at intervals of not less than 30 minutes. The maximum dose 
is the minimum needed to maintain a contraction frequency of 3-4 in ten minutes 
(or) an absolute maximum of 32 milli units per minute. 
RELAXIN:- 
Relaxin has been used both vaginally and intracervically to induce labour 
but studies have failed to show any benefit compared to prostaglandin (Kelly 
2002b). 
Hyaluronidase and estrogen are of historical interest only (Thomas et al 
2001). 
RU 986 OR MIFEPRISIONE:- 
It is a derivative of 19 nor progestin norethindrone containing a dimethyl – 
aminophenol substituent at the 11 beta position it effectively competes with both 
progesterone and glucocorticoids for binding to their respective receptors. 
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This antiprogestin has been studied extensively for preinduction cervical 
ripening at term. 
a. A 200mg dose given orally for 2 days, 48hrs before the formal 
induction Engdman and associates (1992) reported that mifepristone is a 
safe efficient and suitable induction agent for initiation of labour at 
term. 
b. Single dose of 400mg mifepristone was effective for cervical ripening 
and reduce the induction delivery interval ( Giacalone 
PL: Targosz V : Laffargue : Boog G: faure JM). 
c. Induction of labour is facilitated in term women with prior ceasarean 
section by the use of mifepristone. This induction agent appears safe 
and useful with no adverse effect on the fetus or mother (Lelaider c: 
Barton C: Benifla JL, Fernandaz H : Bourget P: Frydman R: (1994). 
d. Single dose of 400 milligram mifepristone (for Preinduction cervical 
ripening in women with an unripe cervix.) is a simple and effective 
treatment ( Stenlund PN: Erkman G: Aedo AR: Bygdeman N 1999). 
e. Mifepristone had a modest effect on cervical ripening when given 24hrs 
before labour induction, appearing to reduce the need for misoprostol 
and oxytocin compared with placebo (Wing Da: Fassect Mj: Mishell 
DR 2000). 
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Amniotomy:- 
 Artificial rupture of membranes can be used to induce labour but implies a 
commitment to delivery. The main disadvantage of amniotomy when used for 
induction is the unpredictable and occasionally long interval, to the onset of 
contractions. 
 There is an increased incidence of chorioamninitis (23 percent) and cord 
compression patterns (12 percents) with early amniotomy. 
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MIFEPRISTONE (RU 486) 
 
Introduction: 
 Mifepristone, a synthetic steroid was discovered in 1980 by Dr. Etienne – 
Emile Beaulieu of France. Mifepristone is an antiprogestin. There are two types of 
antiprogestin 
• Type I -RU486, ZK 112993 
• Type II – ZK 98299. 
Structure: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Mifepristone is a 19 nor steroid, chemically referred to as 11 beta-(4- 
dimethyl amino phenyl)-4, 9-dien-3-one. It is an antiprogestrone. It has a 
molecular formula of C19H35NO2
6
. Its molecular weight is about 429.6. The 
dimethyl amino phenyl side chain at position 11, which is a hydrophilic 
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moiety, appears to be essential for the antiprogestronic activity. It also has 
antiglucocorticoid and antiandrogen activity. 
The structure of the gene encoding both isoforms (PRA and PRB) of the 
progesterone receptor includes the location of the n-terminal initiation codon for 
each isoform (AUGB  and AUGA)8. The basic structure of this gene is shared by 
all members of the steroid, thyroid, vitamin D, retinoic acid and orphan receptor 
superfamily, with five functional domains: an n-terminal transactivation domain 
(A/B), a DNA-binding domain (C), a hinge region (D) and a hormone-binding 
domain (E). Regions important for heat shock protein binding (HSP), nuclear 
translocation (NTS) and transcriptional activation (TAF-I, -II) are also indicated.2 
Mifepristone acts as a competitive receptor antagonist at the progesterone 
receptor in the presence of progesterone and acts as partial agonist in the absence 
of progesterone. Mifepristone at doses greater or equal to 1mg/kg antagonize the 
endometrial and myometrial effects of progesterone. Antiglucocorticoid effect of 
mifepristone is manifested at doses greater or equal to 5.5mg/kg and 
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antiandrogenic effect in animals is seen with prolonged administration of very 
high doses of 10-100mg/kg
26 
III. Receptor binding
 
Progesterone receptor schematic diagram.
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(1) (2) (3)   
     
 
 
1. Transactivation domain 
 
2. DNA binding domain 
 
3. Hormone binding domain 
 
 
 
 The anti progestin action of mifepristone is mediated by the PR, a ligand 
activated transcription factor with domains for DNA binding, hormone binding 
and transactivation. The amino acid glycine at position 722, which is in the 
hormone-binding domain of the human PR, appears to be critical for mifepristone 
binding and action. Substitution of glycine with cysteine in the human PR 
generates a receptor that no longer binds mifepristone. 
Mechanism of action 
Progesterone and mifepristone produce a conformational change in the form 
of the PR that permits it to bind to DNA. 
30 
 
 
Agonist (Progesterone) 
 
 
 
 
 
 
 
 
 
 
 
Antagonist (mifepristone) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PR – Progesterone receptor 
HSP – Heat shock protein 
 
 
In the absence of ligand the progesterone receptor is associated with 
heat shock proteins. Binding of progesterone or mifepristone induces 
conformational changes resulting in dissociation of HSP and dimerization of 
PR. The PR complex binds to specific progesterone response elements in the 
promoter regions of progesterone responsive genes. Progesterone –  PR  
complex is transcriptionally active resulting in agonistic effects whereas 
mifepristone – PR complex is not transcriptionally active resulting in 
antagonistic effects
43
. 
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Under certain circumstances as in the absence of progesterone, mifepristone 
display progesterone agonistic activity It is related to the existence of two isoforms 
of PR, PR-A and PR-B. PR-B behaves as a partial agonist in the presence of 
mifepristone. When PR-A and PR-B are present together the antagonistic effects 
of PR-A can override the agonistic effects of PR-B. So agonistic or antagonistic 
action depends on relative expression of PR-A and PR-B in target tissues. 
Pharmaco Kinetics 
 Mifepristone is administered orally and is readily absorbed. Metabolism in 
splanchnic circulation reduces its bioavailability to 40%. Metabolic clearance rate 
is 0.55l/kg / day. It does not bind to cortisol binding globulin or sex steroid 
binding globulin
34
. 
 Serum mifepristone levels reached a maximum in one hour after oral 
administration of single dose ranging from 50 to 800mg. After single dose of 
100mg or less the disappearance of mifepristone follows first order kinetics with a 
half life of 20-25 hours. After higher doses 200-800mg there is an initial 
redistribution phase of 6-10 hours followed by a plateau in serum levels for 24 
hours or more.  
 The major excretory pathway is fecal with less then 10% being recovered in 
urine. Metabolism involves two step demethylation and hydroxylation. 
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Mifepristone metabolite cross the placental barrier during the second trimester, the 
efficacy of placental transfer decreases with advancing pregnancy.
25
 
Clinical pharmacology: 
Pregnant uterus 
 Mifepristone acts on receptors in decidua resulting in progesterone 
withdrawal to endometrium, disruption of placental function and uterine bleeding. 
Mifepristione stimulate release of PGEF2α.
 36,50,51    
The increase in prostaglandin 
is due to marked reduction in the activity and tissue concentration of prostaglandin 
dehydrogenase, the key enzyme involved in the control of prostaglandin 
catabolism by mifepristone
23
. 
 Mifepristone increases the sensitivity of the myometrium to prosta glandin 
due to increase in number of gap junctions so that synchronization of uterine 
muscle contractility occurs. This causes enhanced electrical activity resulting in 
opening of voltage dependent calcium channels, which causes calcium influx and 
thereby muscle contraction.
59 
 
Mifepristone causes cervical ripening in women undergoing termination of 
pregnancy. Mifepristone causes cervical ripening directly or through the blockage 
of progesterone receptors
54.
 Mifepristone stimulates the release of nitric oxide and 
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the expression of inducible nitric oxide synthase in cervical cells of women. This 
is one of the mechanisms by which mifepristone initiates cervical ripening
57
. 
Other Uses:- 
1. Termination of early pregnancy: 
 Medication abortion became an option for early abortion in India when in 
April 2002; the Drugs Controller General approved the use of mifepristone to 
terminate early pregnancies. 
 In December 2006, the Drugs Controller General of India granted the 
permission to manufacture misoprostol and approved its use for gynecological 
conditions like cervical ripening, prevention of post partum hemorrhage and first 
trimester abortion with mifepristone
55
. While in India, a combination of 
mifepristone and misoprostol is recommended for termination of early pregnancy 
up to 49 days/seven weeks from the last menstrual period (LMP); WHO 
recommends their use up to 63 days or nine weeks from LMP (WHO, 2003).
14 
Mechanism of action: 
 Mifepristone is an anti-progestin, which stops the pregnancy from growing, 
detaches it from the lining of the uterus and softens the cervix.
56,57 
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Recommended Drug Protocol 
Day 1 200mg mifepristone orally. Anti D if Rh-ve 
Day 3 400 mcg misoprostol Analgesics 
Day 15 orally/vaginally. Contraceptive 
 
 
 
 
2. Contraceptive 
 
 
Mifepristone, a novel estrogen free contraceptive when administered in 
low doses daily (2 to 10mg), it inhibits ovulation, menstruation and significantly 
suppresses effects on the endometrium.
33
 However, due to continuation of 
variable degree of follicular development, unopposed estrogen can cause 
hyperplastic or malignant changes in the endometrium. But in 2003, Baird ST et 
al, in their study reported that mifepristone<10mg per day neither caused 
endometrial hyperplasia nor the significant effect on the HPA-axis. Mifepristone 
also maintained bone density, lipids & sense of well being. Mifepristone as a 
postcoital contraceptive inhibits ovulation, blocks implantation by causing a 
delay in maturation of endometrium and causes regression of the corpus luteum 
in the majority of women when given in the middle or late luteal phase
.35,47,53.
 
Two randomized trial have compared 600 mg of mifepristone with the Yuzpe 
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regimen. In these trials single dose of 600mg of mifepristone given within 72 
hours of unprotected intercourse was 100 percent effective as an emergency 
contraceptive.
37 
3. Uterine myoma 
 For safe and effective non-surgical treatment of symptomatic fibroids, high-
dose progestin therapy and GnRh agonists have been shown to decrease overall 
uterine volume by 50 percent at the end of 3 months therapy. So far no therapy has 
been used on a long term basis; therefore, the effect of medical therapy is 
temporary. On a long term basis, mifepristone blocks progesterone dependent 
growth factors, reduces blood supply due to vascular changes and decreases 
inhibition of progesterone estrogen receptor gene transcription by the progesterone 
receptor - A isoform, these are some of the mechanisms causing the 
antiproliferative activity of mifepristone. Mifepristone can be used in uterine 
fibroids as an alternative to GnRh anlogues in the preoperative application and if 
the safety of long term low dose mifepristone is established, perimenopausal 
women with large, symptomatic fibroid could avoid hysterectomies by using 
mifepristone till menopause
45
.
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4. Endometriosis: 
 Mifepristone through antioxidant property does not allow endometriosis to 
proliferate. However, the use of mifepristone for the treatment of endometriosis 
requires additional studies.
46 
5. Ovarian Cancer: 
 Mifepristone inhibits ovarian cancer cells growth by inducing G1 cell cycle 
arrest and blocking the G1-S phase transition without causing cell death. This 
growth arrest is observed by a decline in cyclin – dependent kinase 2 (cdk2) 
protein level and activity. In 2003, Xu M et al reported that ovarian cancer cells 
expressed glucocorticoid receptors. Mifepristone may drive its anticancer action 
by binding to glucocorticoid receptors with an affinity similar to that for 
progesterone receptors and as an antioxidant to drive G1 arrest through a p53 
independent p21. In 2000, Rocereto TF et al in their small trial conducted with 44 
patients suffering from recurrent epithelial ovarian cancer whose tumors had 
become resistant to standard chemotherapy, mifepristone administration showed 
desirable effects against some of the tumors. Thus, mifepristone is a single agent 
potent blocker of ovarian cancer growth, however, the feasibility of using 
mifepristone to enhance the efficacy of conventional chemotherapy for ovarian 
cancer requires further investigations. 
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6. Premenstrual Syndrome: 
 The sex steroid dependency of this disorder has been well established by 
the absence of PMS in castrated women and women treated with GnRH agonist 
analogues. Because the main symptom complex occurs in the luteal phase when 
serum progesterone is at the highest level, it was proposed that an antiprogestin, 
such as RU 486, may be useful in treatment of PMS.
 44  
 Dosing schedules such as 
low dose daily administration to induce a acyclic pattern may yet prove to be 
efficacious in the treatment of PMS. 
7. Ectopic Pregnancy: 
 The role of antiprogestin in the medical therapy of ectopic pregnancy 
remains to be clearly defined. Certainly, the timing, dosing, and efficacy of RU 
486 treatment in this scenario await future studies. 
8. Abnormal Uterine Bleeding: 
 It has been suggested by some that antiprogestins may be useful in 
treatment of dysfunctional uterine bleeding. No clinical experience in this venue 
has been published. If adenomyosis is the etiology of menorrhagia, it may be 
expected that treatment with an antiprogestin may be useful. 
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9. Breast Cancer: 
 It has been observed that estrogen and progesterone in low doses stimulates 
breast cancer growth but in high doses both inhibit breast cancer growth. 
Tamoxifen, the antiestrogen, remains the first line therapy for advanced estrogen-
receptor-positive tumor because of its efficacy, safety and convenience. 
Antiestrogen (Tamoxifen) and antiprogestin produce tumor regression but either 
agent alone only produces tumor stasis. Tamoxifen down regulates the estrogen 
receptor but it favors agonist activities and therefore up regulates the progesterone 
receptor. Mifepristone down regulates both estrogen and the progesterone 
receptors. The finding suggests that tamoxifen cannot inhibit the progestin-
mediated growth-stimulatory effects. Thus, addition of mifepristone to tamoxifen 
effectively reestablishes tamoxifen growth inhibition. It has been observed that 
eventually all advanced breast cancer become hormone independent and 
increasingly resistant to any subsequent therapy as a result there is limitation in 
potential utility of antiprogestin and other endocrine therapies for the treatment of 
advanced disease. 
10. Cushing’s Syndrome: 
 Chronic exposure to excessive corticosteroids in Cushing‟s Syndrome leads 
to the development of multiple metabolic abnormalities such as glucose 
intolerance, dyslipidemia, hypertension, osteoporosis and weight gain. In 2001, 
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Dwight FM et al reported that extremely ill patient with Cushing‟s syndrome, 
treated initially unsuccessfully by a combination of conventional surgical, medical 
and radiotherapeutic approaches responded extremely well up to 25mg/kg/day, 
long term mifepristone, glucocorticoid receptor antagonist therapy. Treatment 
efficacy was confirmed by the normalization of all biochemical glucocorticoid-
sensitive measurements, significant reversal of the patient‟s heart failure, the 
resolution of the psychotic depression and usual return of his HPA axis to normal.
 
28 
11. Meningioma: 
 Most meningiomas have no estrogen receptors but have substantial 
concentrations of progesterone receptors. In patients with unresectable 
meningiomas, objective response and subjective improvement has been noted.
 32
 
Contraindications:- 
 (I) Hemorrhagic disorders (or) concurrent anticoagulant therapy. 
 (II) Inherited Porphyrias 
(III) Chronic adrenal failure  
(IV)History of allergy to mifepristone 
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(V) Concurrent long term corticosteroid therapy (or) recent therapy with    
     corticosteroid. 
(VI) Chronic medical disorders. 
 (VII) Age more than 35years 
(VIII)  Smokers (>10 cigarettes /day). 
Drug interactions: 
 On the basis of this drug metabolism by CYP 3A4, Ketoconazole, 
itraconazole, erythromycin and grape fruit juice may inhibit its metabolism. 
Rifampin, dexamethasone and certain anticonvulsants like phenytoin, 
phenobarbitone and carbamazepine may induce mifepristone metabolism. 
 Mifepristone is contraindicated in the presence of an intrauterine device 
(IUD), ectopic pregnancy, adrenal failure, hemorrhagic disorders, inherited 
porphyria and anticoagulant or long term corticosteroid therapy. 
Side Effects 
 Side effects of short term use include abdominal pain, cramping, nausea, 
vomiting and headache which are dose and treatment duration dependant. Long 
term administration of mifepristone is associated with adrenal insufficiency, low 
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serum potassium levels, a slight increase in serum creatinine levels, moderate 
increase in hepatic enzymes and significant increase in thyrotrophins levels. 
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MATERIALS AND METHODS 
 
 This prospective clinical trial was carried out in the Department of 
obstetrics and gynaecology, K.A.P.V Medical college hospital,MGMGH,Trichy 
during the period from  January 2016 to December 2016 
 The purpose of the study was to evaluate the safety and efficacy of 
mifepristone as an orally active inducing agent in women with unfavourable 
cervix at term (Bishop score < 4). 
Inclusion Criteria 
1. Post dated uncomplicated pregnancy. 
2. Intra uterine fetal death. 
3. Gestational hypertension. 
4. Primigravida less than 35 years and uncomplicated multigravida up to 
three pregnancies. 
5. Intact membranes during the time of induction. 
6. No contraindications for prostaglandins or mifepristone. 
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Exclusion Criteria 
1. Premature rupture of membranes. 
2. Malpresentations. 
3. Cephalopelvic disproportion. 
4. Bad obstetric history or history of previous abortions. 
5. Previous history of caesarean section or any uterine surgery. 
6. Multiple pregnancy. 
7. Placental complications like abruption or placenta praevia. 
8. Abnormal fetal heart rate patterns. 
9. Parity > 3 
10. Active herpes infection. 
11. Contra indication for prostaglandins. 
12. Chorioamnionitis 
 On admission, a detailed history, and complete general and obstetric 
examination was carried out. Vaginal examination was done under strict aseptic 
precautions and the cervical status, fetal station were assessed. Gestational age 
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calculated by Naegle‟s rule and a routine obstetric scan for fetal maturity and well-
being was done. Once the inclusion criteria were fulfilled and 
cephalopelvicdisproportion was ruled out, the patient was prepared and transferred 
to the labour ward. Indication for induction was noted after reaffirming that there 
was no contraindication for induction. 
Informed Consent 
 A detailed written informed consent was obtained from the participant and 
her relatives. The following were addressed in the consent form. Indication for 
induction of labour, drug to be administered with its dosage and mode of 
administration, side effect of the drug, risks associated with the administration of 
these drugs and if complications arise, alternative mode of termination were all 
discussed. 
Treatment Schedule 
Group – I 
 50 pregnant women were given tablet mifepristone 200mg orally on day1. 
They were observed for maternal vitals, uterine activity, bleeding or draining pv 
and fetal heart rate. After the wait period of 24 hours or when the Bishop score 
was ≥ 6, when the cervical dilatation was > 2cm, or when the membranes ruptured 
or when the patient was well in labour whichever is earlier labour was accelerated 
with oxytocin drip,if the bishop score is 4 or less induced with cerviprime gel. 
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Group – II 
 50 pregnant women pregnant were given placebo on day 1. They were 
observed for maternal vitals,uterine activity,bleeding or draining pv and fetal heart 
rate. After the wait period of 24hours ,depending on the Bishop score they were 
either induced with cerviprime gel or augmented with oxytocin drip. 
Monitoring of the patients 
 Maternal vitals, uterine activity and fetal heart rate were monitored 
clinically. Partogram was maintained for all patients and used to record all the 
clinical events during the course of labour. A watch for the rupture of membranes 
was done. If membranes not ruptured ARM was done at 3cm cervical dilatation. 
Pervaginal examination was done if there was rupture of membranes or once in 4 
hours in active phase of labour. The pulse rate, blood pressure, temperature and 
urine output were recorded . Delivery particulars duration of each stage of labour 
blood loss at third stage of labour and baby particulars were recorded.Mother and 
baby were observed for postnatal complications if any. 
 Data were analysed and all the values were expressed as mean ± standard 
deviation or as percentages. Statistical comparison were performed by students 
paired and unpaired t-test and chi-square test. Statistically significant difference 
(P<0.05). 
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The efficacy was assessed by the following criteria: 
1. Favourability of Bishop score at 24 hrs. 
2. Need for induction with cerviprime gel 
3. The need of oxytocin for augmentation. 
4. Duration of labour. 
5. Drug administration to delivery interval. 
6. The mode of delivery. 
7. Cesarean section rate. 
8. The 5 minute Apgar score, neonatal complications and incidence of    
           neonatal mortality. 
9. Maternal complications. 
Success of induction was assessed by the following criteria: 
1. Patients who delivered vaginally within 48 hours of the start of 
induction. 
2. Bishop score of ≥ 6 at the end of 24 hours 
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Failure of induction was assessed by the following criteria: 
1. Patients who delivered vaginally after 48 hours of start of induction. 
2. Patients who underwent caesarean section. 
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RESULTS AND OBSERVATION 
 
Table 1 Age distribution of the study population (n=100) 
Age group 
Mifepristone 
group 
N (%) 
Placebo group 
N (%) 
Total 
N (%) 
<20 years 13 (26) 16 (32) 29 (29) 
21- 25 years 25 (50) 22 (44) 47 (47) 
26 – 30 years 10 (20) 10 (20) 20 (20) 
31 to 35 years 2 (4) 2 (4) 4 (4) 
Total 50 (100) 50 (100) 100 (100) 
 
Mean age: 23.18 years,  Standard deviation: 3.614 years 
 Minimum: 19 years,  Maximum: 34 years 
Chi-square value: 0.502, p value: 0.918 
Comments: Age distribution of the 2 groups were similar and the minor 
difference observed was not statistically significant (p>0.05).Hence both the 
groups are comparable. 
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Fig 1: Bar chart showing age distribution of the study population 
(n=100) 
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Table 2 Distribution of the study population according to parity 
(n=100) 
Parity 
Mifepristone 
group 
N (%) 
Placebo group 
N (%) 
Total 
N (%) 
Primigravida 30 (60) 36 (72) 66 (66) 
Multigravida 20 (40) 14 (28) 34 (34) 
Total 50 (100) 50 (100) 100 (100) 
 
Chi-square value: 1.604, p value: 0.205 
Comments: The difference in distribution of the study population 
according to parity was not statistically significant (p>0.05) between the groups. 
Hence both the groups are comparable. 
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Fig 2: Bar chart showing distribution of the study population 
according to parity (n=100) 
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Table 3 Distribution of the study population according to indication 
for induction of labor (n=100) 
Indication for induction 
Mifepristone 
group 
N (%) 
Placebo group 
N (%) 
Total 
N (%) 
Prolonged pregnancy 37 (74) 37 (74) 74 (74) 
Gestational hypertension 11 (22) 12 (24) 23 (23) 
IUGR 2 (4) 1 (2) 3 (3) 
Total 50 (100) 50 (100) 100 (100) 
 
Chi-square value: 0.377, p value: 0.828 
Comments: The difference in indications for induction of labor was not 
statistically significant (p>0.05) between the groups. 
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Fig 3: Bar chart showing distribution of the study population 
according to indication for induction of labor (n=100) 
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Table 4 Comparison of bishop score among the two groups (n=100) 
Student “T” test 
Bishop score at 
baseline 
Mean 
score 
Std. 
Deviation 
Mean 
difference 
p value 
95% confidence 
interval 
Mifepristone 
group 
1.48 0.953 
0.360 0.057 
 
-0.011 to 0.731 
Placebo group 1.12 0.918 
 
Bishop score 
after 24 hours 
Mean 
score 
Std. 
Deviation 
Mean 
difference 
p value 
95% confidence 
interval 
Mifepristone 
group 
6.26 1.536 
3.80 <0.001 3.271 to 4.329 
Placebo group 2.46 1.092 
 
Comments: 
1. Subjects in the Mifepristone group were not so different from subjects in 
placebo group with the respect to Bishop score at baseline as the mean 
difference was not statistically significant (p>0.05).  
2. However, Subjects in the Mifepristone group had a higher Bishop score 
after 24 hours than subjects in placebo group and this difference was 
statistically significant. 
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Fig 4: Box plot showing distribution of the study population 
according to bishop score at 0 hours among the two groups (n=100) 
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Fig 5: Box plot showing distribution of the study population 
according to bishop score at 24 hours among the two groups (n=100) 
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Table 5 Distribution of the study population according to need for 
augmentation with oxytocin (n=100) 
Augmentation with 
oxytocin 
Mifepristone 
group 
N (%) 
Placebo group 
N (%) 
Total 
N (%) 
Needed 20 (40) 27 (54) 47 (47) 
Not needed 30 (60) 23 (46) 53 (53) 
Total 50 (100) 50 (100) 100 (100) 
Chi-square value: 1.967, p value: 0.161 
Comments:  
 The difference in need for augmentation of labor with oxytocin was not 
statistically significant (p>0.05) between the 2 groups.  
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Fig 6: Bar chart showing distribution of the study population 
according to need for augmentation with oxytocin (n=100) 
 
  
20
27
30
23
0
10
20
30
40
50
60
Mifepristone group Placebo group
Augmentation with oxytocin Needed
Not needed
59 
 
Table 6 Distribution of the study population according need for 
Dinoprotone (cerviprime) gel (n=100) 
Dinoprotone gel 
Mifepristone 
group 
N (%) 
Placebo group 
N (%) 
Total 
N (%) 
Needed 9 (18) 47 (94) 56 (56) 
Not needed 41 (82) 3 (6) 44 (44) 
Total 50 (100) 50 (100) 100 (100) 
 
Chi-square value: 58.604, p value: <0.001 
Comments:  
 Very few Subjects in the Mifepristone needed cervical priming 
withDinoprotone gel than subjects in placebo group and this difference was 
statistically significant. Hence the use of oral Mifepristone greatly reduces the 
need for cervical priming with Dinoprotone gel. 
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Fig 7: Bar chart showing distribution of the study population according to 
need for Dinoprotone (cerviprime) gel (n=100) 
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Table 7 Comparison of number of doses of Dinoprotone gel administered 
among the two groups (n=56) Student “T” test 
 
Number of 
doses of 
Dinoprotone gel 
(N) 
Mean 
number 
of doses 
Std. 
Deviation 
Mean 
difference 
p value 
95% confidence 
interval 
Mifepristone 
group (9) 
1.00 0.001 
-0.510 0.012 -0.905 to 0.117 
Placebo group 
(47) 
1.51 0.585 
 
 
 
Comments:  
Among the subjects who needed cervical priming with Dinoprotone gel, 
subjects in the Mifepristone group needed fewer doses than subjects in placebo 
group and this difference was statistically significant. Hence the use of oral 
Mifepristone greatly reduces the not only the need for cervical priming with 
Dinoprotone gel but also the number of doses needed. 
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Table 8 Distribution of the study population according to mode of 
delivery (n=100) 
mode of delivery 
Mifepristone 
group 
N (%) 
Placebo 
group 
N (%) 
Total 
N (%) 
 
p value 
Labor naturalis 46 (92) 32 (64) 78 (78) 
 
0.004 
Outlet forceps 
delivery 
2 (4) 4 (8) 6 (6) 
 
0.958 
LSCS 2 (4) 14 (28) 16 (16) 
 
0.009 
Total 50 (100) 50 (100) 100 (100) 
 
- 
Chi-square value: 12.179, p value: 0.002 
Comments:  
 The difference in mode of delivery was statistically significant (p>0.05) 
between the 2 groups with fewer subjects in the mifepristone group needing 
LSCS. 
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Fig 8: Bar chart showing distribution of the study population 
according to mode of delivery (n=100) 
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Table 9  Distribution of the study population according to indication 
for LSCS (n=16) 
Indication for 
LSCS 
Mifepristone 
group 
N (%) 
Placebo 
group 
N (%) 
Total 
N (%) 
Failed induction 0 (0) 6 (42.9) 6 (37.5) 
Fetal distress 2 (100) 8 (57.1) 10 (62.5) 
Total 2 (100) 14 (100) 16 (100) 
 
Chi-square value: 1.371, p value: 0.242 
Comments:  
 The difference in indication for LSCS was not statistically significant 
(p>0.05) between the 2 groups. 
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Fig 9: Bar chart showing distribution of the study population 
according to indication for LSCS (n=16) 
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Table 10 Comparison of time duration from induction to active stage 
of labor among the two groups (n=84)  
Student “T” test 
Time duration 
from induction 
to active stage 
(N) 
Mean 
duration 
Std. 
Deviation 
Mean 
difference 
p value 
95% confidence 
interval 
Mifepristone 
group (48) 
24.083 3.0323 
-6.166 <0.001 -7.359 to -4.973 
Placebo group 
(36) 
30.250 2.2313 
 
 
Comments:  
Subjects in the Mifepristone group progressed about 6 hours (mean 
difference) earlier than subjects in placebo group to active stage of labor and 
this difference was statistically significant. Also the use of oral mifepristone 
shortened the duration from induction to active stage ranging from 5 hours to 7 
hours based on the 95% confidence interval. 
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Fig 10 Box plot of time duration from induction to active stage of 
labor among the two groups (n=84) 
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Table 11 Comparison of time duration from induction to delivery among 
the two groups (n=84) 
Student “T” test 
Time duration 
from induction 
to delivery (N) 
Mean 
duration 
Std. 
Deviation 
Mean 
difference 
p value 
95% confidence 
interval 
Mifepristone 
group (48) 
28.604 3.3437 
-6.840 <0.001 -8.14 to -5.539 
Placebo group 
(36) 
35.444 2.3627 
 
Comments:  
 Subjects in the Mifepristone group progressed to delivery in about 7 
hours (mean difference) earlier than subjects in placebo group and this 
difference was statistically significant. Also the use of oral mifepristone 
shortened the duration from induction to delivery in the range of 5 hours 30 
minutes to 8 hours based on the 95% confidence interval. 
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Fig 11 Box plot of time duration from induction to delivery of labor 
among the two groups (n=84) 
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Table 12 Distribution of the study population according time of 
vaginal delivery from induction in both groups (n=84) 
 
Vaginal delivery 
Mifepristone 
group 
N (%) 
Placebo 
group 
N (%) 
Total 
N (%) 
≤ 24 hours 11 (22.9) 0 (0) 11 (13.1) 
25 to 48 hours  37 (77.1) 36 (100) 73 (86.9) 
Total 48 (100) 36 (100) 16 (100) 
 
Chi-square value: 9.493, p value: 0.002 
 
Comments:  
About 23% of patients who were given oral mifepristone delivered within 
24 hours while all the patients in the placebo group delivered between 25 to 48 
hours duration from induction and this difference is statistically significant.  
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Fig 12 Bar chart of time duration from induction to vaginal delivery 
among the two groups (n=84) 
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Table 13 Comparison of birth weight among the two groups (n=100) 
Student “T” test 
 
Birth weight 
(N) 
Mean 
Birth 
weight 
Std. 
Deviation 
Mean 
difference 
p value 
95% confidence 
interval 
Mifepristone 
group (50) 
2.918 0.4079 
-0.038 0.606 -0.183 to 0.107 
Placebo group 
(50) 
2.956 0.3208 
 
 
Comments:  
 There was no statistically significant difference in the mean birth weight 
between the 2 groups. 
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Table 14 Comparison of Apgar score among the two groups (n=100) 
Student “T” test 
 
Apgar 
score 
Group 
Mean 
Birth 
weight 
Std. 
Deviation 
Mean 
difference 
p 
value 
95% 
confidence 
interval 
0 
minutes 
Mifepristone 5.46 0.973 
0.540 0.004 0.172 to 0.908 
Placebo 4.92 0.877 
5 
minutes 
Mifepristone 7.38 0.753 
0.460 0.003 0.156 to 0.764 
Placebo 6.92 0.778 
 
 
Comments: 
  There was a statistically significant difference in the mean apgar score 
between the 2 groups both at 0 minutes and 5 minutes with babies born to the 
subjects in the Mifepristone group having a better apgar score than those born to 
the subjects in placebo group. 
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Fig 13 Box plot of Comparison of Apgar score among the two groups 
(n=100) 
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Table 15 Distribution of the study population according to maternal 
complications (n=100) 
 
Maternal 
complications 
Mifepristone 
group 
N (%) 
Placebo group 
N (%) 
Total 
N (%) 
Fever 2 (4) 5 (10) 7 (7) 
GI symptoms 3 (6) 3 (6) 6 (6) 
Abdominal cramps 4 (8) 0 4 (4) 
Uterine contractile 
abnormalities 
0 4 (8) 4 (8) 
PPH 0 1 (2) 1 (2) 
Puerperal sepsis 0 0 0 
No complications 41 (82) 37 (74) 78 (78) 
Total 50 (100) 50 (100) 100 (100) 
 
Chi-square value: 10.491, p value: 0.062 
Comments:  
 The difference in occurrence of maternal complications was not 
statistically significant (p>0.05) between the 2 groups.  
 76   
 
Table 16 Distribution of the study population according to fetal complications 
(n=100) 
 
 
Fetal complications 
Mifepristone 
group 
N (%) 
Placebo 
group 
N (%) 
Total 
N (%) 
Respiratory distress 2 (4) 3 (6) 5 (5) 
Meconium 
aspiration 
syndrome 
2 (4) 5 (10) 7 (9) 
Transient 
tachypnea of 
newborn 
1 (2) 0 (0) 1 (1) 
No complications 45 (90) 42 (84) 87 (87) 
Total 50 (100) 50 (100) 100 (100) 
 
Chi-square value: 2.589, p value: 0.459 
Comments: 
  The difference in occurrence of fetal complications was not statistically 
significant (p>0.05) between the 2 groups. 
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Table 17 Distribution of the study population according to need for NICU 
admission of the babies (n=100) 
 
 
NICU admission 
Mifepristone 
group 
N (%) 
Placebo 
group 
N (%) 
Total 
N (%) 
No 46 (92) 42 (84) 88 (88) 
Yes 4 (8) 8 (16) 12 (12) 
Total 50 (100) 50 (100) 100 (100) 
 
Chi-square value: 1.515, p value: 0.218 
 
Comments:  
 The difference in need for NICU admission of the babies was not 
statistically significant (p>0.05) between the 2 groups. 
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Fig 14 Bar chart of showing fetal complications among the two groups 
(n=100) 
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DISCUSSION 
 
 
The process of labor initiation remains a mystery. It is well known, however, that 
progesterone is integral in the maintenance of pregnancy. It is hypothesized that anti 
progestin exposure in pregnancy will enhance the initiation of parturition. 
Mifepristone a progesterone antagonist is a steroid compound which may soften 
the cervix and cause uterine contractions. This medication has been shown to be effective 
for elective abortions and medical termination of pregnancy during the first trimester. 
This lead others to study the effect of mifepristone in term pregnancies. Results of these 
studies have demonstrated that mifepristone may ripen the cervix and induce labor while 
not increasing the risk to the fetus. 
In this study, study population comprised of 100 patients with equal number of 
patients in the study and control group. There were no significant statistical differences 
between the treatment groups in demographics or medical or obstetrics history. 
66 (66%) patients were primigravida,24(24%) were multigravida, with no 
significant difference across the groups. 
The mean bishop score at inclusion was 1.48 in the study group and 1.12 in the 
control group with no significant differences between the groups. The success rate was 
higher when the Bishop score at inclusion was 3 or 4 (P <0.0001). A study done by Elliot 
60
 and colleagues compared the effects of 50 mg and 200 mg of oral mifepristone with 
placebo on cervical ripening and labor induction in primigravid women with unfavorable 
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cervices at term. At a dose of 200 mg, mifepristone resulted in a favorable cervix or 
spontaneous labor more often than did placebo. 
Treatment was successful (onset of labor and/or a bishop score >/= 6 before or at 
the time of reassessment for study and control group) in 40 (80%) women in study group 
when compared to 2 (4%) women in the control group. 
There are many studies comparing mifepristone with placebo. 
A similar comparison was observed in a study by Wing DA 
61 
et al who reported 
that 54 percent normal women given 200 mg Mifepristone daily for two consecutive days 
went into labor within 72 hours compared with only 18.2 percent of those given a 
placebo. 
In a RCT study done by Berkane 
10 
et al which compared mifepristone with 
placebo showed that treatment was successful in about 52.7% of the patients assessable 
for efficacy with no significant difference among the groups (P=0.73). 
A study done by Karl et al stated that mifepristone treated group was successful in 
52.7% of patients when compared with placebo. Another randomized control trial by 
Giacalone 
17 
et al from France also proved that mifepristone is effective for cervical 
ripening and reduced the time to delivery when compared with placebo. 
23 (76%) nulliparous women had favorable improvement in bishop score when 
compared to 17 (85%) parous women in study group. A study done by Nadia 
10 
et al 
showed that the relationship between parity and success rate was close to significance (P 
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= 0.053). This is comparable to the study by Berkane 
10 
et al which stated that the rate of 
vaginal delivery increases with parity. 
The mean treatment to induction to active stage interval was 24.08 hours in the 
mifepristone treated group when compared to 30.25 hours in the placebo treated group.  
Subjects in the Mifepristone group progressed about 6 hours (mean difference) 
earlier than subjects in placebo group to active stage of labor and this difference was 
statistically significant. Also the use of oral mifepristone shortened the duration from 
induction to active stage ranging from 5 hours to 7 hours based on the 95% confidence 
interval. 
Mean induction to delivery interval was 28.60 in mifepristone group when 
compared to 35.44 in placebo group.Subjects in the Mifepristone group progressed to 
delivery in about 7 hours (mean difference) earlier than subjects in placebo group and this 
difference was statistically significant. Also the use of oral mifepristone shortened the 
duration from induction to delivery in the range of 5 hours 30 minutes to 8 hours based 
on the 95% confidence interval. 
A Cochrane review 2009 
38 
said that compared to placebo mifepristone treated 
women were less likely to have an unfavorable cervix at 48 hours (RR – 0.39) or at 96 
hours (RR- 0.39). Further the review stated that mifepristone treated women were more 
likely have delivery within 48 and 96 hours of treatment than with the placebo treated 
group. 
 82   
 
A study done by Frydman
11 
 et al said that the mean interval between the time of 
induction and the onset of labor was significantly shorter in the mifepristone treated 
group. 
A study done by Berkane 
10 
 et al showed that as the dose of mifepristone 
increased the interval between the treatment and onset of labor, and between the 
treatment and delivery tended to be shorter. The difference was significant between 
600mg mifepristone and placebo. 
A study done by Karl et al stated that labor was prolonged in the groups who 
received lower doses of mifepristone than those who received 400 or 600 mg.  
A study done by Josie 
62 
 et al stated that women treated with mifepristone are 
more likely to have a favorable cervix within 48 to 96 hours when compared with 
placebo. 
Another study by Zhonghua et al from Beijing stated that the cervical ripening 
ratio was 100% in the mifepristone treated group. 
Another study from Sweden 
63
 , department of women and child health says that 
the median time taken from the onset unto delivery is relatively lower in groups with 
mifepristone than the control group.A similar French study  stated that the onset of labor 
was one day earlier in the mifepristone treated group when compared with placebo. 
The rate of normal and assisted vaginal deliveries was 96% in the mifepristone 
treated group when compared to 72% in the placebo treated group with a significant P 
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value. A similar comparison was observed by an RCT by Wing et al 
61
 who stated that 
87.5% women in the mifepristone treated group were delivered vaginally 48 hours after 
the start of treatment than 70% in the placebo treated group. 
Another study by Zhonghua et al from Beijing stated that the incidence of vaginal 
delivery was 80.8% in the mifepristone treated group. 
The rate of caesarean deliveries (28.3%) was comparably less in the mifepristone 
treated group than the prostaglandin treated group (46.6%). 
A Cochrane review  in 2009 said that the mifepristone treated women were less to 
undergo caesarean section (RR -0.71). Another prospective study done by Mcgill 
21
 et al 
United Kingdom showed that the rate of caesarean section was significantly lower among 
women induced with mifepristone alone. 
A similar comparison was found in a study by Josie et al who stated that the 
mifepristone treated women were less likely to undergo caesarean section 
Of the 2 (4%) mifepristone treated women who underwent caesarean section both 
were done in view of fetal distress.   Among the 14(28%) placebo treated women 6(12%) 
cases were for failed induction,8(16%) cases were done for fetal distress.  
Meconium passage in utero occurred in 2 (4%) infants of the mifepristone treated 
group which is more when compared to 5 (10%) infants in the placebo treated group. In a 
study by Wing 
61
 et al where meconium passage was 9.1% in the mifepristone treated 
group. 
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Abnormal FHR pattern was found were found in1 (2%) cases of the mifepristone 
treated group and 18 (16%) cases of the placebo treated groups. 
But a Cochrane review  2009 stated that the rate of abnormal FHR pattern was 
higher in the mifepristone treated group. Another study by Wing 
61
 et al stated than the 
rate of fetal distress was higher in the mifepristone treated group. 
In our study the difference in Apgar score at 1 min and at 5 min was statistically 
significant  between the study and control group. 4 (8%) infants in the study group and 
8(16%) infant in the control group required admission in NICU.  
A Cochrane review 
38
 in 2009 said that the incidence of neonatal hypoglycemia 
might be more common after exposure to mifepristone (it antagonizes the action of 
glucocorticoids as well as the action of progesterone). 
Another study done by Karl et al stated that there was no difference in fetal 
tolerability and the rate of fetal distress. A study done by clamart  et al from France says 
that mifepristone appears safe and useful with no adverse effects on the fetus or mother 
There was no significant difference in the maternal heart rate (beats/min) or 
systolic or diastolic blood pressure in both the study and control group which is 
comparable to a study by Nadia 
10
 et al where in there was no significant difference. 
Another study by Wing et al also stated that there were no adverse uterine abnormalities 
or maternal complications observed in the mifepristone treated groups. 
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The need for reinduction with dinoprostone gel was less with mifepristone treated 
groups (18%) when compared with the placebo treated groups (94%) which is 
statistically significant.The need for augmentation with oxytocin was less with study 
group (40%) when compared to placebo group (54%). 
A RCT done by Frydman 
11
 et al suggested that the need for oxytocin was much 
lesser in the mifepristone treated group when compared with placebo. Another French 
11
 
study stated that women treated with mifepristone had more spontaneous labor and lesser 
doses of augmentation. 
Another study by Wing 
61
 et al stated that the dose and amount of oxytocin 
required was lesser in the mifepristone treated group. 
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Mifepristone has proved very useful for medical abortion in the first and second 
trimester termination of pregnancy. It has an established role as an effective cervical 
priming agent. This effect is now utilized for cervical ripening in term pregnancies. 
Mifepristone is well tolerated by pregnant women and the efficacy which has been 
proved in many trials. 
There are a few reports in the literature describing the effect of mifepristone as a 
pre induction cervical ripening agent for term pregnancies. However available data do 
show that mifepristone is better than a placebo at ripening the cervix or inducing labor. 
In our study we compared the effect of mifepristone with placebo. 
In our study we found that mifepristone as a pre induction cervical ripening agent 
had better proven efficacy especially in primigravida women as similarly proved by 
various other earlier standard trials. The need for  reinduction/augmentation with other  
cerviprime agents/oxytocics were also reduced in the mifepristone treated groups. 
Theoretically, mifepristone has appeal as a method of inducing labor in women 
with previous caesarean section as it does not involve administering exogenous oxytocic 
drugs that have potential to over stimulate. There is evidence of a possible reduction in 
the incidence of caesarean section following mifepristone treatment (compared to 
placebo) that would justify further trials quoted as per the reviews of Cochrane 
38 
2009. 
Maternal Complications were similar in both groups. 
This study aimed to assess the safety and efficacy of mifepristone as a pre 
induction cervical ripening agent in term pregnancies and to study its adverse effects on 
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mother and fetus. The results are encouraging with no significant adverse effects on 
mother and fetus. Further efforts can be put forth to probe the study further and prove the 
effectiveness of the drug and its efficacy. Further studies can be done comparing 200 mg 
of mifepristone with 400 mg or even higher doses if found favorable. It promises to be a 
more compliant drug in near future. 
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PROFORMA 
 
 
 
Name: Age DOA: 
  DOD: 
Address: IP.No L.M.P: 
 SES E.D.D: 
 
 
HISTORY:    
™ History of Presenting complaints Booked Case: Yes/No. 
™ Obstetric History  Gr P L A 
 
 Menstrual History 
 
 Past Medical / Surgical History 
 
 Personal History 
 
 Family History 
 
 
GENERAL PHYSICAL EXAMINATION   
Height Weight BMI  
Pallor Edema   
Pulse BP RR Temperature 
CVS RS Breast Thyroid 
 
 
Per Abdomen – Uterine Size  Activity 
 
    - Lie    Presentation  Position 
 
   - FHR 
 
  
 
 
Per Speculum 
 
Per Vaginum  - Cx Dilatation  Position Consistency 
 
Effacement 
 
Integrity of membranes 
 
Presentation and Station 
 
Pelvic Assessment 
 
 
 
INVESTIGATIONS 
 
1. Hb% 
 
2. Urine-albumin  
 
 Sugar  
 Deposits 
 
3. Bloodgroup&Rh typing 
 
4. Blood-urea 
 
-Sugar 
 
5. Serum creatinine 
 
6. HIV, VDRL, HBSAG 
 
7. Obstetric scan – single, live/dead, fetus 
 
- Cardiac activity&fetal movements  
- B.P.D- cms weeks days 
- F.L - cms weeks days 
- Placenta-fundal anterior/posterior  
- Grade  maturity  
- Liquor  adequate/not  
- Obvious congenital abnormalities  
 
  
 
Bishop score on admission- 
 
Indication for induction-  
Date and time of induction- 
 
 
 
Bishop score at time of induction- 
 
Wait period after induction 
 
Bishop score at the end of 24 hrs 
Need for cerviprime gel induction 
Need for oxytocin 
 
DURATION OF LABOUR 
 
Induction to active stage(hrs) 
Induction to delivery interval(hrs) 
 
 
NATURE OF DELIVERY 
 
Labour 
Instrumental delivery   
    
Lscs 
Indication 
 
Low 
midcavity 
forceps 
  
Natural/labour 
natural 
with episiotomy 
Outlet 
forceps 
 
Vacuum 
delivery 
 
 
 
 
 
 
Amount of blood loss at III stage 
 
Drug administration to delivery interval 
 
Complications-Maternal 
 
Nausea/vomiting/diarrhea 
 
Headache/hyperthermia/fever 
 
Abdominal cramps 
 
Chorioamnionitis/endometritis/puerperal sepsis,  
  
  
 
Uterine contraction abnormalities-Tachysystole/ hypertonus/ Hyperstimulation.  
 
 
Any Treatment Given  
Intrapartum Fetal Complications 
  
1. Fetal heart rate abnormalities 
 
2. Meconium passage-thin/thick 
 
 
BABY  
Birth weight  
Apgar 1’ 5’ 
 
 
Congenital anomalies if any 
Neonatal resuscitation Neonatal 
admissions 
 
Fetal complications-Meconium aspiration syndrome – 
Hyperbilirubinemia 
 
-Others 
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1 Shunmugapriya 28 28846 M 40w 5d PP 1 6 - Yes 23 27 LN   
Fever   
3.1 7 8 No 
2 Thenmozhi 20 29068 P 40W 1d PP 0 4 1 - 26 29 LN       3.1 5 7 No 
3 Viji 21 28650 P 40W 3d PP 2 6 - - 24 28 LN     RD 3 6 8 No 
4 Nithya 24 15102 P 38W GHT 1 6 - - 23 28 LN   
A.cramps   
2.7 5 7 No 
5 Vaishnavi 25 12203 M 40W 2d PP 2 8 - - 20 24 LN       3.2 6 8 No 
6 Ayisha Beevi 24 11024 P 40W PP 0 4 1   28 32 LN       3.2 5 7 No 
7 Parveen 22 10430 P 39 GHT 2 6 - Yes 26 29 LN   
    
2.5 6 8 No 
8 Nivenitha 22 10948 P 34 GHT 2 7 - - 22 24 LN   
  MEC 
1.2 4 6 Yes 
9 Saranya 20 10898 M 40W PP 2 8 - - 24 28 LN   A.cramps   2.8 6 8 No 
10 Aruna devi 26 31129 M 40W 2d PP 0 6 - Yes 23 27 LN       3.2 6 7 No 
11 Abiramasundari 28 30290 P 40W 3d PP 1 6 - Yes 24 32 LN   
    
3.5 5 7 No 
12 Kasthuri 19 29099 P 40W 5d PP 2 8 - - 22 26 LN       3 6 8 No 
13 Rajalakshmi 20 31749 P 40W 4d PP 1 6 - Yes 28 32 LN       3 5 7 No 
14 Rose mary 26 32270 P 40W 5d PP 0 3 1 - - - LSCS FD 
  MEC 
3 4 6 Yes 
15 Chinnaponnu 32 32567 M 38 GHT 2 8 - - 20 22 LN   
    
3.1 6 8 No 
16 Suganya 21 32593 P 39 IUGR 2 6 - Yes 28 32 LN - 
    
2.4 4 6 No 
17 Priya 22 32988 M 38 GHT 0 4 1 - 28 32 LN - 
    
2.5 5 7 No 
18 Deepalakshmi 23 33152 P 40W 1d PP 2 6   Yes 26 31 LN   
    
2.7 5 7 No 
19 Mahalashmi 30 33267 M 40W  PP 2 8 - - 20 24 LN       2.7 6 8 No 
20 Saranya 20 33261 M 38W SP 2 6 1 - 24 29 LN   A.cramps   3.2 4 6 NO 
21 Thangammal 19 34747 P 40W 2d PP 0 6 - Yes 20 24 LN       2.7 6 8 No 
22 Priyanka 25 34371 P 39W GHT 0 4   - 28 33 LN   
    
2.7 5 7 No 
23 Shanthi 21 34608 M 40W 2d PP 1 8 - - 19 24 LN   GI   3.1 8 9 No 
24 Swarnalatha 22 33841 P 40W 3d PP 1 6 - Yes 25 31 LN       3 5 7 No 
25 Nirmala 20 36285 P 37W 5d IUGR 0 6   Yes 22 25 LN   
    
2.2 4 6 Yes 
26 Maheshwari 20 33372 P 40W 5d PP 2 8   No 23 29 LN       3.4 6 8 No 
27 Munishwari 24 36308 M 40W 1d PP 2 8 - - 23 28 LN   Fever   2.8 5 7 No 
28 Gunavathi 22 35769 P 40W 5d PP 2 6 - Yes 27 32 Outlet   
    
3.5 5 7 Yes 
29 Santhoshi 21 34913 P 39W GHT 0 4   YES 26 33 LN   
    
2.4 5 7 No 
30 Suba 24 35019 M 40W 5d PP 2 6 - Yes 24 29 LN       3 7 8 No 
31 Ganga 20 34736 P 40W 5d PP 2 6 - Yes 28 31 LN       3.2 5 7 No 
32 Banupriya 25 37317 P 37W GHT 1 6   Yes 26.5 31 LN   
    
2.6 5 7 No 
33 Saradha 19 37785 M 40W 5d PP 2 8 - - 19.5 24 LN       3.2 6 8 No 
34 Prabhavathi 22 37750 P 40W 2d PP 0 4 1 - 29.5 33 LN     TTN 3.1 5 7 No 
35 Caroline 21 37981 P 38W GHT 3 7 - Yes 23.5 29 LN   
    
2.7 5 7 No 
36 Sandhya 19 38476 P 40W 1d PP 3 8 - - 19 24 LN       3.5 6 8 No 
37 Jenova Mary 27 39388 P 40W 2d PP 2 6 - - 24 29 LN       3.3 5 7 No 
38 Indra 24 386060 M 40W 1d PP 2 6   Yes 28.5 33 LN       3 5 7 No 
39 Gowdhami 24 39116 M 40W 2 d PP 2 8 - - 19 24 LN       3.9 6 8 No 
40 Thenmozhi 30 38745 P 40W PP 0 2 1 -     LSCS FD A.cramps 
  
2.8 5 7 No 
41 Bhaghyavathi 27 38614 M 40W 5d PP 2 8 - - 25 30 LN   
    
3.1 6 8 No 
42 Priyadharshni 20 38278 P 37W GHT 2 6 - Yes 24 29 LN   
GI   
2.6 5 7 No 
43 Revathi 19 38194 P 40W  PP 3 8 - - 23 27 LN     RD 3 6 8 No 
44 Deepa 31 34728 M 40W 2d PP 2 6 1 - 20 24 LN       3 5 8 No 
45 Radhika 23 75032 M 40W 1d PP 2 8 - - 24 27 LN       3 8 9 No 
46 Deepa 22 32428 P 40W PP 1 6 - Yes 28 34 LN       2.6 4 7 No 
47 Nandhini 21 72010 M 40W 1d PP 3 8 - - 29 33 LN       2.7 5 7 No 
48 
Bhuvaneshwari 30 72127 P 37W GHT1 2 6 - Yes 24 32 Outlet   
GI   
2.8 6 8 No 
49 Udhaya Surya 26 38140 M 40W PP 3 8 - - 20 24 LN   
    
3 8 9 No 
50 Pandiyammal 23 38120 M 40W 1d PP 1 4 1 - 25.5 31 LN   
    
2.9 5 7 No 
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1 FATHIMA BEEVI 29 29579 M 40W2d PP 1 3 1   28.5 32 LN   GI   3.2 4 6 NO 
2 LALITHA 20 31374 P 40W PP 0 2 2   28 34 OUTIET     RD 3.5 4 5 YES 
3 PRIYADARSHINI 22 15628 P 40W1D PP 2 3 2   30 36.5 LN   HS   3 4 6 NO 
4 RAMYA 24 13422 P 37 GHT 1 2 1 YES 26 32 LN       2.7 5 7 NO 
5 SARADHA 24 15371 M 40WID PP 1 3 - YES 28.5 32 LN   Fever   3 6 7 NO 
6 INDHUMATHI 24 15256 P 40W2D PP 0 2 2 -     LSCS FD     3 4 7 NO 
7 MEENA 20 10894 P 39 GHT 1 2 1 YES     LSCS FI     2.5 5 7 NO 
8 SHANMUGAVALLI 21 31793 P 36 GHT 2 4 1 YES 26 32 LN       3 6 8 NO 
9 MEGALA 21 29068 P 40W1D PP 0 2 2 - 30 36 LN   PPH   3.4 5 6 YES 
10 SARANYA 22 31659 M 40W3D PP 1 2 1 YES 32 38 LN       3.2 6 7 NO 
11 PARAMESHWARI 27 29249 P 40W2D PP 2 4 2   28 34 LN       3 4 6 YES 
12 KOUSALYA 20 30883 P 40W1D PP 1 3 2   32.5 36 LN       2.8 5 7 NO 
13 PRIYA 20 82053 P 40W3D PP 1 2 2       LSCS FI Fever   2.7 6 8 N0 
14 MANICKAM 26 33083 P 40W1D PP 0 2 2                       
15 CHITHRA 28 32736 M 38 GHT 2 4 1 YES 31.5 36 LN       2.9 5 6 NO 
16 SHALINI 20 33249 P 38 GHT 0 2 1 YES     LSCS FD   RD 2.6 4 6 YES 
17 DIVYA 21 32671 M 39 GHT 0 2 2   30 34     HS   3.2 5 7 NO 
18 GOWRI 21 32917 P 40W2D PP 2 2 3       LSCS FI   RD 3 5 7 NO 
19 MEGALA 31 34013 M 40W1D PP 2 4   YES 28 32.5 LN       2.9 6 8 NO 
20 KOKILA 20 33787 P 38 GHT 2 2 2       LSCS FD   MEC 3 4 7 NO 
21 RESHMA 20 33951 P 40W1D PP 0 2 1 YES 30 36 LN       2.5 4 7 NO 
22 RANI 19 33028 P 38 GHT 0 1 2   34 39.5 LN   Fever   2.6 5 8 NO 
23 DURGADEVI 24 34675 M 40W1D PP 1 2 1   28.5 34 OUTLET   HS   3.5 4 7 NO 
 24 ANUSIYA 22 34553 P 40W2D PP 1 2 1 YES 30 34 LN       2.9 6 7 NO 
25 SANGEETHA 19 33693 P 37 IUGR 0 2 1 YES 32 36 LN     MEC 2.2 4 6 YES 
26 NAGALAKSHMI 30 32883 P 40W4D PP 0 2 2       LSCS FD     3.2 4 7 NO 
27 ANEESFATHIMA 21 35562 M 40W2D PP 2 2 1 YES 28 33.5 LN       2.7 6 8 NO 
28 BHUVANESHWARI 20 34514 P 40W4D PP 2 4 2   34 39 LN       3.5 7 8 NO 
29 SUGANYA 22 35277 P 39 GHT 0 0 2       LSCS FD     2.3 4 6 YES 
30 SATHYA 30 34778 P 40W1D PP 2 2 1 YES 31 36 LN       2.8 5 7 NO 
31 NAGALAKSHMI 21 37609 P 40W1D PP 1 4 1 YES 30 34 LN   Fever   3.2 4 7 NO 
32 MAHALAKSHMI 24 37662 M 40W2D PP 0 2 1 YES 28 36 LN       3.5 5 7 NO 
33 KARTHIKA 20 37505 P 40W3D PP 0 2 2   32.5 37 LN       2.8 6 8 NO 
34 VIJAYALAKSMI 24 61657 P 40W1D PP 1 0 2 YES 34 40 OUTLET       3.3 4 6 YES 
35 MUTHULAKSHMI 23 37851 P 38 GHT 0 2 1       LSCS FD   MEC 2.9 4 7 NO 
36 MALLIGA 19 38261 P 40W1D PP 1 3 1   30 34.5 LN       2.7 5 7 NO 
37 SUSEELA 20 39377 P 40W2D PP 1 1 2 YES     LSCS FI     3.2 5 7 NO 
38 KALAIYARASI 26 39150 M 40W3D PP 2 4 1 YES 30 34 LN   GI   3.2 6 8 NO 
39 NILOFERNISHA 25 38892 M 40W1D PP 2 4 1 YES 32 36 LN       3.2 4 7 NO 
40 PREMA 29 38589 P 40W    PP 3 6   YES 28 32.5 LN       2.7 6 8 NO 
41 NIROSHA 19 38507 P 40W 1D PP 2 2 2   30 37 LN       3.3 5 7 NO 
42 ISHWARYA 21 38788 P 37W GHT 3 3 1 YES 29 36 LN       2.4 4 6 NO 
43 DHANALAKSHMI 19 71582 P 40W 3D PP 0 2 2 YES     LSCS FI     3 5 6 NO 
44 RADHIKA 19 74943 M 40W 1D PP 2 2 1 YES 34 40 LN       3.3 6 7 NO 
45 GANGA 22 75090 M 40W 4D PP 2 2 1 YES     LSCS FD     3.2 4 6 NO 
46 VIDHYA 28 38428 P 40W 1D  PP 0 2 1 YES     LSCS FD Fever MEC 2.8 4 6 NO 
47 MUTHUJEEVA 34 34732 M 40W 2D PP 1 3 1 YES 32 37 LN       2.7 6 8 NO 
48 DEEPIKA 23 72197 P 37W GHT 2 2 2   34 40 OUTLET   GI MEC 2.9 4 6 YES 
49 MALLIKA 28 73428 P 40W 3D PP 2 4 1 YES 30 34 LN       2.5 6 8 NO 
50 VINOTHA 22 32478 P 40W 1D PP 2 2 3       LSCS FI HS   3.2 5 7 NO 
  
 
KEY TO MASTER CHART 
 
IP No  - Inpatient Number 
 
 
P  - Primigravida 
M  - Multigravida 
GA  - Gestational Age 
PP  - Prolonged pregnancy  
GHT  - Gestational Hypertension. 
IUGR  - Intrauterine Growth Retardation 
NICU  - Neonatal intensive Care Unit 
FHA  - Fetal Heart rate abnormality 
MEC  - Meconiun stained. 
RD  - Respiratory distress 
FD  - Fetal distress  
FI  - Failed induction  
TTN  - Transient Tachypnoea of Newborn  
HS  - Hyperstimulation   
